The board of directors of Moberg Derma AB (publ.) has decided to withdraw the proposed listing on NASDAQ OMX Stockholm, as the demand from investors was not sufficient to ensure a successful post IPO life on the stock exchange.

Today Moberg Derma AB (publ.) (”Moberg Derma”) has published a supplement to the previously published prospectus regarding offer to subscribe for shares in Moberg Derma. The supplementary prospectus has been prepared following the press release on 3 December 2010 in which Moberg Derma announces that Moberg Derma has signed an agreement for distribution in Switzerland.

Moberg Derma AB (publ.) has entered into a distribution agreement with Gebro Pharma AG S.A. for Emtrix® – for treatment of discolored and deformed nails resulting from fungal infection  (onychomycosis) or psoriasis, and Kaprolac® – for problems with dry and flaky skin and. Under the agreement, Gebro is granted exclusive rights to market and sell Emtrix®, Kaprolac® Dandruff Shampoo and Kaprolac® Scalp Solution in Switzerland and the Principality of Lichtenstein.

Today Moberg Derma AB (publ) (”Moberg Derma”) has published a supplement to the previously published prospectus regarding offer to subscribe for shares in Moberg Derma. The supplementary prospectus has been prepared due to that Moberg Derma on November 16, 2010 has been granted the permit to initiate a clinical phase II-trial for MOB-015 from the Swedish Medical Products Agency.

The Swedish Medical Products Agency has granted Moberg Derma permit to initiate a clinical phase II trial for MOB-015. MOB-015 is Moberg Dermas next generation topical treatment for nail fungus, with fungicidal, keratolytic and emollient properties.   

The Board of Directors of Moberg Derma AB (publ) has applied for a listing of its shares on NASDAQ OMX Stockholm, the main list. In connection with the listing, Moberg Derma will broaden the ownership through a new issue of SEK 140m.

Moberg Derma AB today announced that a distribution agreement has been entered into with Laboratorio EDOL Produtos Farmaceuticos S.A. for Emtrix® – Moberg Derma’s product for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement EDOL is granted exclusive rights to market and sell Emtrix® in Portugal and ten markets in Africa and Central America. Moberg Derma will manufacture Emtrix® for EDOL.

Moberg Derma’s market partner in the Nordic countries – Antula Healthcare, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals – has now launched sales of Nalox™ in the Nordic region. Pharmacies have displayed great interest in Moberg Derma’s product Nalox™ – a treatment for discoloured and damaged nails caused by nail fungus or nail psoriasis.

Moberg Derma has acquired a credit facility totaling SEK 50 million. The agreement runs for two years. The facility will be used to finance day-to-day operations. The facility may be drawn on as required from 1 January 2011.

Moberg Derma AB, Sweden, today announced a commercial agreement with Perrigo Company that covers distribution in Israel for Moberg Derma’s novel topical nail product Emtrix™ – a treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Moberg Derma assumes supply responsibility, while the distributor will be responsible for registration and promotion in Israel.

Moberg Derma AB, Sweden, today announced a commercial agreement for the Middle East. The agreement covers distribution in eight countries for Moberg Derma’s novel topical nail product Emtrix™ – a treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Moberg Derma assumes supply responsibility, while the distributor will be responsible for registration and promotion in the Middle East.

At Moberg Derma´s annual general meeting of 22 April 2010, Mats Pettersson was elected new chairman of the board and Wenche Rolfsen deputy chairman. Mats Pettersson replaces Ingemar Aldén, who resigned after four years as chairman of the board.

Moberg Derma AB, Sweden and Medical Futures Inc, Canada (“MFI”), today announced a commercial license agreement. The license covers distribution in Canada for Moberg Derma’s novel topical nail product – a treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Moberg Derma assumes supply responsibility, while MFI will be responsible for promotion in the Canadian market. Financial terms include payments for product supply and milestones.

Moberg Derma AB today announced that CE mark has been granted for its topical product for the management and relief of common scalp conditions associated with scaly and itchy skin, e.g. seborrhoeic eczema and dandruff. The CE mark provides authorization to market and sell the medical device product in the EU/EEA. The company also announced that it received ISO 13485 certification.

Moberg Derma AB today announced that CE-mark has been granted for the company’s first approved medical device product, used for the treatment of discolored and damaged nails, for example caused by nail fungus (onycomycosis) or nail psoriasis. The CE mark provides authorization to market and sell the product in the EU/EEA.